» Articles » PMID: 20978089

From Emergence to Eradication: the Epidemiology of Poliomyelitis Deconstructed

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 2010 Oct 28
PMID 20978089
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Poliomyelitis has appeared in epidemic form, become endemic on a global scale, and been reduced to near-elimination, all within the span of documented medical history. Epidemics of the disease appeared in the late 19th century in many European countries and North America, following which polio became a global disease with annual epidemics. During the period of its epidemicity, 1900-1950, the age distribution of poliomyelitis cases increased gradually. Beginning in 1955, the creation of poliovirus vaccines led to a stepwise reduction in poliomyelitis, culminating in the unpredicted elimination of wild polioviruses in the United States by 1972. Global expansion of polio immunization resulted in a reduction of paralytic disease from an estimated annual prevaccine level of at least 600,000 cases to fewer than 1,000 cases in 2000. Indigenous wild type 2 poliovirus was eradicated in 1999, but unbroken localized circulation of poliovirus types 1 and 3 continues in 4 countries in Asia and Africa. Current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with B-cell immunodeficiencies. Beyond the current efforts to eradicate the last remaining wild polioviruses, global eradication efforts must safely navigate through an unprecedented series of endgame challenges to assure the permanent cessation of all human poliovirus infections.

Citing Articles

Global Impact of Mass Vaccination Campaigns on Circulating Type 2 Vaccine-Derived Poliovirus Outbreaks: An Interrupted Time-Series Analysis.

Cooper L, Bandyopadhyay A, Grassly N, Gray E, Voorman A, Zipursky S J Infect Dis. 2025; 231(2):e446-e455.

PMID: 39873524 PMC: 11841638. DOI: 10.1093/infdis/jiae614.


Individual and community level maternal factors for zero-dose children in Ethiopia using mini-EDHS 2019: a mixed effects model.

Agimas M, Alemayehu M, Tesfie T, Tilahun W, Asferie W, Aweke M BMJ Open. 2025; 15(1):e085235.

PMID: 39773798 PMC: 11749608. DOI: 10.1136/bmjopen-2024-085235.


Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence During Roll-Out of Type-2 Novel Oral Polio Vaccine.

Peak C, Lyons H, Voorman A, Gray E, Cooper L, Blake I Vaccines (Basel). 2025; 12(12.

PMID: 39771970 PMC: 11680014. DOI: 10.3390/vaccines12121308.


Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management.

Estivariz C, Krow-Lucal E, Mach O Pathogens. 2025; 13(12).

PMID: 39770387 PMC: 11677883. DOI: 10.3390/pathogens13121128.


Geospatial mapping to assess the distribution and determinants of zero dose vaccination status hot spots among children in Ethiopia using EDHS 2019: Spatial and geographical weighted regression.

Agimas M, Asmamaw M, Hailu M, Kidie T, Abuhay H, Yismaw G PLoS One. 2024; 19(12):e0312610.

PMID: 39739825 PMC: 11687766. DOI: 10.1371/journal.pone.0312610.


References
1.
Torok T, Kilgore P, Clarke M, Holman R, Bresee J, Glass R . Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. National Respiratory and Enteric Virus Surveillance System Collaborating Laboratories. Pediatr Infect Dis J. 1997; 16(10):941-6. DOI: 10.1097/00006454-199710000-00007. View

2.
Kew O, Wright P, Agol V, Delpeyroux F, Shimizu H, Nathanson N . Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ. 2004; 82(1):16-23. PMC: 2585883. View

3.
Sutter R, Caceres V, Mas Lago P . The role of routine polio immunization in the post-certification era. Bull World Health Organ. 2004; 82(1):31-9. PMC: 2585885. View

4.
POLAND J, PLEXICO K, Flynt J, CHIN T . Poliovirus neutralizing antibody levels among preschool children. Public Health Rep (1896). 1968; 83(6):507-12. PMC: 1891069. View

5.
MacLennan C, Dunn G, Huissoon A, Kumararatne D, Martin J, OLeary P . Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004; 363(9420):1509-13. DOI: 10.1016/S0140-6736(04)16150-3. View